Prognostication of Prostatic Adenocarcinoma
The prognosis of prostatic adenocarcinoma is determined by integrating clinical stage (TNM), Gleason score (Grade Group), and serum PSA level into validated risk stratification schemes, with these three factors serving as the essential foundation for predicting biochemical recurrence, metastasis, and cancer-specific mortality. 1
Core Prognostic Framework
Risk stratification using stage, grade, and PSA must be performed for every newly diagnosed patient to guide treatment selection and predict outcomes. 2, 3 This approach provides superior prognostic accuracy compared to clinical stage alone and has been extensively validated across multiple patient cohorts. 1
Essential Prognostic Variables
The three mandatory factors for risk assessment are: 3
- Clinical T stage (determined by digital rectal examination)
- Gleason score/Grade Group (from biopsy specimen)
- Serum PSA level (ng/mL)
Additional refinement can be achieved by incorporating: 4, 5
- Percentage of positive biopsy cores (number of cores with cancer divided by total cores obtained)
- Primary Gleason pattern (whether pattern 3 or 4 predominates in Gleason score 7 tumors)
- Tumor volume on biopsy specimens
NCCN Risk Categories and Prognosis
Very Low/Low Risk
Patients with T1-T2a, Gleason score ≤6 (Grade Group 1), and PSA <10 ng/mL have excellent prognosis. 1, 2 The 5-10 year cancer-specific mortality is very low for these patients. 2 However, even Gleason 3+3=6 disease possesses malignant histological features and capability for extraprostatic extension, though metastatic risk remains minimal. 6
Intermediate Risk: Critical Heterogeneity
Intermediate-risk disease (T2b-T2c, Gleason 7, or PSA 10-20 ng/mL) demonstrates substantial prognostic heterogeneity that mandates further substratification. 1, 5
Favorable Intermediate Risk
Defined by all three of the following: 5
- Predominant Gleason grade 3 (Gleason 3+4=7, Grade Group 2)
- <50% of biopsy cores positive
- ≤1 NCCN intermediate-risk factor present
These patients have outcomes approaching low-risk disease, with 5-year distant metastasis rates of only 1.6%. 5
Unfavorable Intermediate Risk
Defined by any of the following: 5
- Primary Gleason pattern 4 (Gleason 4+3=7, Grade Group 3)
- ≥50% positive biopsy cores
- >1 NCCN intermediate-risk factor present simultaneously
These patients experience significantly worse outcomes, with 5-year distant metastasis rates of 5.4% and markedly lower PSA recurrence-free survival compared to favorable intermediate-risk patients. 5 The primary Gleason pattern distinction is critical: patients with Gleason 4+3 have significantly higher rates of biochemical recurrence, more advanced pathologic stage, and larger tumor volumes compared to Gleason 3+4 patients. 7
High Risk
Patients with T3a, Gleason score 8-10 (Grade Groups 4-5), or PSA >20 ng/mL face substantially elevated risk of progression and cancer-specific mortality. 1, 2
Within Gleason 8-10 disease, further prognostic stratification exists: 8, 9, 10
- Gleason 4+4=8 organ-confined disease: 33-month actuarial progression risk of 32%, with outcomes not predictable by preoperative variables. 9
- Gleason 8-10 with PSA <11 ng/mL and pathologic stage pT2: Significantly better 5-year progression-free survival (54-80%) compared to pT3 disease (27-40%). 8
- Gleason score composition matters: 10-year prostate cancer death risk is 0.45 for Gleason 4+5,0.56 for Gleason 5+4, and 0.66 for Gleason 5+5, demonstrating prognostic heterogeneity even within Grade Group 5. 10
Predictive Tools Beyond Risk Groups
Partin Tables
The Partin tables predict pathologic stage (organ-confined, extracapsular extension, seminal vesicle invasion, or lymph node metastasis) by combining clinical stage, Gleason score, and PSA, providing probability estimates with 95% confidence intervals. 2, 1, 4
Nomograms
Nomograms provide more individualized predictions than risk groups because they integrate multiple prognostic variables continuously rather than categorically. 2 They can predict: 1, 11
- Biochemical progression-free survival after definitive therapy
- Likelihood of adverse pathologic features at prostatectomy
- Success of salvage radiation after failed surgery
- Appropriateness of active surveillance
Critical limitation: Current models do not predict with perfect accuracy, and only some predict metastasis and cancer-specific death rather than just biochemical recurrence. 2, 1
PSA Kinetics and Long-Term Outcomes
PSA doubling time after biochemical failure is more clinically relevant than PSA failure alone for predicting mortality. 2, 1 Patients with short PSA doubling times face greatest risk of death from prostate cancer. 1 The median delay between PSA rise and metastasis development is 8 years, with median time from metastasis to death being 5 years. 4
Tissue-Based Genomic Biomarkers
Genomic biomarkers (Prolaris, Oncotype Dx, Decipher) should not be routinely used but may be selectively employed when added risk stratification could alter clinical decision-making. 3 These tests have shown association with biochemical recurrence, metastasis, and prostate cancer death, but most validation studies used prostatectomy rather than biopsy specimens. 3
Critical Pitfalls in Prognostication
- Do not rely solely on Gleason 3+4 versus 4+3 distinction: A Gleason 3+4 tumor remains unfavorable intermediate-risk if ≥50% cores are positive or multiple intermediate-risk factors coexist. 5
- When counting positive cores from MRI-targeted biopsies: Multiple cores from the same targeted lesion should be counted as a single core to avoid artificially inflating the percentage. 5
- Minimum 15-year follow-up is necessary to properly evaluate treatment efficacy for localized disease, given the long natural history and competing mortality risks. 4
- Not all PSA failures are clinically relevant: Many men with biochemical recurrence will not develop metastases or die from prostate cancer due to competing causes of mortality. 2, 1